Last reviewed · How we verify
Tazarotene 0.045% Lotion
Tazarotene is a retinoid that binds to retinoid receptors to regulate gene expression and reduce skin inflammation and abnormal keratinocyte differentiation.
Tazarotene is a retinoid that binds to retinoid receptors to regulate gene expression and reduce skin inflammation and abnormal keratinocyte differentiation. Used for Plaque psoriasis, Acne vulgaris.
At a glance
| Generic name | Tazarotene 0.045% Lotion |
|---|---|
| Also known as | Arazlo |
| Sponsor | Dr. Emmy Graber |
| Drug class | Retinoid |
| Target | Retinoid X receptor (RXR), Retinoid acid receptor (RAR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Tazarotene is a third-generation retinoid that selectively activates retinoid X receptors (RXR) and retinoid acid receptors (RAR), particularly RAR-beta and RAR-gamma. This activation modulates gene transcription involved in cell differentiation, proliferation, and inflammatory responses in the skin. The drug normalizes keratinization and reduces inflammatory cytokine production, making it effective for treating psoriasis and acne.
Approved indications
- Plaque psoriasis
- Acne vulgaris
Common side effects
- Skin irritation (erythema, burning, pruritus)
- Photosensitivity
- Peeling and dryness
- Worsening of acne (retinization)
Key clinical trials
- Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults (PHASE3)
- A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis (PHASE4)
- Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis (PHASE4)
- Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis (PHASE4)
- Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis (NA)
- Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne (PHASE4)
- A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis. (EARLY_PHASE1)
- A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tazarotene 0.045% Lotion CI brief — competitive landscape report
- Tazarotene 0.045% Lotion updates RSS · CI watch RSS
- Dr. Emmy Graber portfolio CI